VG Life Sciences Inc (VGLS) 0.0119 $VGLS
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 10.24 (+0.15), PFE: 35.81 (+0.24), OMER: 11.41 (+0.18), ICPT: 143.47 (-2.89), ABBV: 61.96 (-0.75), IONS: 24.47 (+0.05), NVS: 81.76 (-0.95)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 8.05 (-0.15), NWBO: 0.48 (-0.12)
Research and Markets: Pre-Eclampsia Pipeline Review, H2 2015 Edition Featuring A1M Pharma AB, Alnylam Pharmaceuticals, Glenveigh Medical, Pluristem Therapeutics, rEVO Biologics & VG Life Sciences
BusinessWire - Fri Oct 23, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbms42/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H2 2015" report to their offering.
Pre-Eclampsia Pipeline Review, H2 2015 Edition Featuring A1M Pharma AB, Alnylam Pharmaceuticals, Glenveigh Medical, Pluristem Therapeutics, rEVO Biologics & VG Life Sciences
M2 - Fri Oct 23, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pd92nl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pre-Eclampsia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pre-Eclampsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pre-Eclampsia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics, Inc. - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/pd...eeclampsia
PSTI: 1.32 (-0.03), RBIO: ()
VG Life Sciences Notes Major Achievements and New Grants in Third Quarter 2015
PR Newswire - Thu Oct 08, 5:30AM CDT
Dear Shareholders,
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.41 (+0.05), PFE: 35.81 (+0.24), INCY: 79.68 (-1.59), AZN: 30.16 (-0.26), AVEO: 0.93 (-0.01), AMGN: 154.26 (-0.02)
VGLS Notes Key Patents, License and Other Major Achievements in the First Half of 2015
PR Newswire - Tue Jun 16, 3:28PM CDT
Dear Shareholders,
Global Pre-Eclampsia Therapeutics Pipeline Review, H1 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Jun 05, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78h8rl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics - VG Life Sciences, Inc. Drug Profiles - ALN-AGT - Alpha-1-Microglobulin - antithrombin alfa (recombinant) - digoxin immune fab - Monoclonal Antibodies for Cardiovascular Diseases - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Stem Cell Therapy for Pre-Eclampsia - VG-1177 For more information visit http://www.researchandmarkets.com/research/78...eeclampsia
PSTI: 1.32 (-0.03), RBIO: ()
Global Lyme Disease Pipeline Report 2015 - 4 Companies & 7 Drug Profiles
M2 - Wed May 20, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fttftx/lyme_disease) has announced the addition of the "Lyme Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - LondonPharma Ltd - Valneva SE - VG Life Sciences, Inc. Drug Profiles - azithromycin gel - lyme borreliosis vaccine - lyme disease vaccine - lyme disease vaccine 2 - Small Molecule for Lyme Disease - VGV-L - VLA-15 For more information visit http://www.researchandmarkets.com/research/ft...me_disease
BAX: 45.31 (-0.14)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 2.03 (-0.15), CNCE: 11.46 (+0.26), ATHX: 2.29 (+0.07), KPTI: 6.97 (-0.22), CUR: 0.28 (-0.02)
VG Life Sciences Granted Key Composition Of Matter Patent
PR Newswire - Mon Mar 02, 6:00AM CST
VG Life Sciences, Inc., (OTCQB: VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 10.24 (+0.15), PFE: 35.81 (+0.24), OMER: 11.41 (+0.18), ICPT: 143.47 (-2.89), ABBV: 61.96 (-0.75), IONS: 24.47 (+0.05), NVS: 81.76 (-0.95)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 8.05 (-0.15), NWBO: 0.48 (-0.12)
Research and Markets: Pre-Eclampsia Pipeline Review, H2 2015 Edition Featuring A1M Pharma AB, Alnylam Pharmaceuticals, Glenveigh Medical, Pluristem Therapeutics, rEVO Biologics & VG Life Sciences
BusinessWire - Fri Oct 23, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbms42/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H2 2015" report to their offering.
Pre-Eclampsia Pipeline Review, H2 2015 Edition Featuring A1M Pharma AB, Alnylam Pharmaceuticals, Glenveigh Medical, Pluristem Therapeutics, rEVO Biologics & VG Life Sciences
M2 - Fri Oct 23, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pd92nl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pre-Eclampsia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pre-Eclampsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pre-Eclampsia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics, Inc. - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/pd...eeclampsia
PSTI: 1.32 (-0.03), RBIO: ()
VG Life Sciences Notes Major Achievements and New Grants in Third Quarter 2015
PR Newswire - Thu Oct 08, 5:30AM CDT
Dear Shareholders,
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.41 (+0.05), PFE: 35.81 (+0.24), INCY: 79.68 (-1.59), AZN: 30.16 (-0.26), AVEO: 0.93 (-0.01), AMGN: 154.26 (-0.02)
VGLS Notes Key Patents, License and Other Major Achievements in the First Half of 2015
PR Newswire - Tue Jun 16, 3:28PM CDT
Dear Shareholders,
Global Pre-Eclampsia Therapeutics Pipeline Review, H1 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Jun 05, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78h8rl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics - VG Life Sciences, Inc. Drug Profiles - ALN-AGT - Alpha-1-Microglobulin - antithrombin alfa (recombinant) - digoxin immune fab - Monoclonal Antibodies for Cardiovascular Diseases - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Stem Cell Therapy for Pre-Eclampsia - VG-1177 For more information visit http://www.researchandmarkets.com/research/78...eeclampsia
PSTI: 1.32 (-0.03), RBIO: ()
Global Lyme Disease Pipeline Report 2015 - 4 Companies & 7 Drug Profiles
M2 - Wed May 20, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fttftx/lyme_disease) has announced the addition of the "Lyme Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - LondonPharma Ltd - Valneva SE - VG Life Sciences, Inc. Drug Profiles - azithromycin gel - lyme borreliosis vaccine - lyme disease vaccine - lyme disease vaccine 2 - Small Molecule for Lyme Disease - VGV-L - VLA-15 For more information visit http://www.researchandmarkets.com/research/ft...me_disease
BAX: 45.31 (-0.14)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 2.03 (-0.15), CNCE: 11.46 (+0.26), ATHX: 2.29 (+0.07), KPTI: 6.97 (-0.22), CUR: 0.28 (-0.02)
VG Life Sciences Granted Key Composition Of Matter Patent
PR Newswire - Mon Mar 02, 6:00AM CST
VG Life Sciences, Inc., (OTCQB: VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
